Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs)
Summary
The purpose of this phase I/II study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .
General Information
NCT#: NCT03767582
Study ID: J18163
Trial Phase: Phase I/II
Trial Sponsor: Bristol-Myers Squibb, Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: GVAX, Nivolumab, BMS-813160